While two complement-targeting drugs (pegcetacoplan and avacincaptad pegol, targeting C3 and C5, respectively) have been approved for the treatment of geographic atrophy in AMD (127, 128), both are extracellular inhibitors. This evidence concerns the gene C3 and age-related macular degeneration.